Lead Product(s) : Patidegib
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study
Details : SGT-610 (patidegib) is a topical gel formulated, small molecule, Hedgehog signaling pathway Inhibitor drug, which is being investigated for the treatment of Gorlin syndrome.
Product Name : SGT-610
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 30, 2023
Lead Product(s) : Patidegib
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Patidegib
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Raymond James & Associates
Deal Size : $12.8 million
Deal Type : Public Offering
Details : The Company intends to use the net proceeds from the Offerings to fund the acquisition of SGT-610, the topically-applied patidegib, a new chemical entity hedgehog signaling pathway blocker, for the treatment of Gorlin syndrome.
Product Name : SGT-610
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 27, 2023
Lead Product(s) : Patidegib
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Raymond James & Associates
Deal Size : $12.8 million
Deal Type : Public Offering
Lead Product(s) : Patidegib
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Sol-Gel Technologies
Deal Size : $74.7 million
Deal Type : Acquisition
Details : SGT-610 (patidegib), an Orphan Drug candidate, broadens Sol-Gel’s pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome, if approved by the FDA.
Product Name : SGT-610
Product Type : Other Small Molecule
Upfront Cash : $4.7 million
January 27, 2023
Lead Product(s) : Patidegib
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Sol-Gel Technologies
Deal Size : $74.7 million
Deal Type : Acquisition
Lead Product(s) : Patidegib
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Phyton Biotech LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PellePharm’s patedigib topical gel is an investigational treatment to be used for rare dermatologic conditions. This is the first step in efforts to enable the renewable production of cyclopamine.
Product Name : SGT-610
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 01, 2021
Lead Product(s) : Patidegib
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Phyton Biotech LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Patidegib
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Poster titled "A Phase 1, Single-center, Pharmacokinetic, Safety and Tolerability Study of Patidegib Topical Gel in Healthy Adult Volunteers Under Maximum Use Conditions" including other studies will be presented at the conference.
Product Name : SGT-610
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 29, 2020
Lead Product(s) : Patidegib
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PellePharm announced it has dosed the first two participants in a Phase 2 clinical trial of Patidegib Topical Gel, 2%, vs. vehicle gel for people with non-Gorlin High Frequency Basal Cell Carcinoma.
Product Name : SGT-610
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 01, 2020